title: Pazopanib for metastatic pulmonary epithelioid hemangioendothelioma-a suitable treatment option: case report and review of anti-angiogenic treatment options.
abstract: BACKGROUND
  Epithelioid hemangioendothelioma is a rare vascular tumor of borderline or low-grade malignancy. The lungs and liver are the two common primary organs affected. Metastatic disease was reported in more than 100 cases in the literature. However, no firm conclusions can be determined for recommended treatment options.
  
  
  METHODS
  The current case presents a patient with metastatic pulmonary epithelioid hemangioendothelioma to the cervical and mediastinal lymph nodes, lungs and liver that has been treated with pazopanib for more than two years with PET avid complete metabolic response in the mediastinum and lungs, and long-lasting stable disease. Target therapies that block VEGFR have a logical base in this rare malignancy.
  
  
  CONCLUSIONS
  The current case is the first to report objective, long-lasting response to pazopanib.
authors.affiliation: Integrated Oncology and Palliative Care Unit, Rambam Health Care Campus and Technion-Israel Institute of Technology, POB 9602, Haifa, 31096, Israel. v_semenysty@rambam.health.gov.il.
authors.forename: Valeriya
authors.initials: V
authors.lastname: Semenisty
authors.affiliation: Institute of Pathology, Rambam Health Care Campus and Technion-Israel Institute of Technology, Haifa, Israel. i_naroditzky@rambam.health.gov.il.
authors.forename: Inna
authors.initials: I
authors.lastname: Naroditsky
authors.affiliation: Department of Nuclear Medicine, Rambam Health Care Campus and Technion-Israel Institute of Technology, Haifa, Israel. z_keidar@rambam.health.gov.il.
authors.forename: Zohar
authors.initials: Z
authors.lastname: Keidar
authors.affiliation: Integrated Oncology and Palliative Care Unit, Rambam Health Care Campus and Technion-Israel Institute of Technology, POB 9602, Haifa, 31096, Israel. g_barsela@rambam.health.gov.il.
authors.forename: Gil
authors.initials: G
authors.lastname: Bar-Sela
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D018323:Hemangioendothelioma, Epithelioid / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D007191:Indazoles; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D049268:Positron-Emission Tomography; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D013449:Sulfonamides / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D007191:Indazoles; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; C516667:pazopanib; D040262:Receptors, Vascular Endothelial Growth Factor